These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2895394)

  • 21. [Determination of matrix components in the synovial fluid and blood--a novel approach to studying cartilage involvement in joint disease].
    Saxne T
    Nord Med; 1989; 104(6-7):184-6, 188. PubMed ID: 2734093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical aspects, diagnosis, treatment and etiology of pyrophosphate arthropathy].
    Bjelle A
    Lakartidningen; 1980 Jun; 77(24):2253-7. PubMed ID: 6249980
    [No Abstract]   [Full Text] [Related]  

  • 23. Joint and systemic distribution of dialysis amyloid.
    Athanasou NA; Ayers D; Rainey AJ; Oliver DO; Duthie RB
    Q J Med; 1991 Mar; 78(287):205-14. PubMed ID: 2047516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Plasma and synovial fibronectin. Results of personal research].
    Lecocq J; North ML; Grange D; Hauptmann G; Kuntz JL; Meyer R; Asch L
    Rev Rhum Mal Osteoartic; 1984; 51(7-8):393-8. PubMed ID: 6494778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship of angiogenesis factor in synovial fluid to various joint diseases.
    Brown RA; Tomlinson IW; Hill CR; Weiss JB; Phillips P; Kumar S
    Ann Rheum Dis; 1983 Jun; 42(3):301-7. PubMed ID: 6859962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ultra-microcrystals in pyrophosphate arthropathy. Crystal identification and case report.
    Bjelle A; Crocker P; Willoughby D
    Acta Med Scand; 1980; 207(1-2):89-92. PubMed ID: 6245562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiogenic factor from synovial fluid resembling that from tumours.
    Brown RA; Weiss JB; Tomlinson IW; Phillips P; Kumar S
    Lancet; 1980 Mar; 1(8170):682-5. PubMed ID: 6103093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical concentrations of aluminium in water used for dialysis.
    Hodge KC; Day JP; O'Hara M; Ackrill P; Ralston AJ
    Lancet; 1981 Oct; 2(8250):802-3. PubMed ID: 6116918
    [No Abstract]   [Full Text] [Related]  

  • 29. Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout).
    Russell RG; Bisaz S; Fleisch H; Currey HL; Rubinstein HM; Dietz AA; Boussina I; Micheli A; Fallet G
    Lancet; 1970 Oct; 2(7679):899-902. PubMed ID: 4097282
    [No Abstract]   [Full Text] [Related]  

  • 30. Amyloid, advanced glycation end products, and dialysis related arthropathy.
    McDonald SP; Coates PT; Disney AP
    Ann Rheum Dis; 1998 Apr; 57(4):193-5. PubMed ID: 9709172
    [No Abstract]   [Full Text] [Related]  

  • 31. Hydroxyproline metabolism in serum, synovial fluid ans synovial membrane in joint diseases.
    Igari T; Tsuchizawa M; Obara K; Ono S
    Nihon Geka Hokan; 1968 Nov; 37(6):836-41. PubMed ID: 5751724
    [No Abstract]   [Full Text] [Related]  

  • 32. Low aluminium water, desferrioxamine, and dialysis encephalopathy.
    Milne FJ; Sharf B; Bell PD; Meyers AM
    Lancet; 1982 Aug; 2(8296):502. PubMed ID: 6125670
    [No Abstract]   [Full Text] [Related]  

  • 33. Letter: Aluminium and dialysis encephalopathy.
    Platts MM; Hislop JS
    Lancet; 1976 Jul; 2(7976):98. PubMed ID: 59177
    [No Abstract]   [Full Text] [Related]  

  • 34. Cytologic, cytochemical and immunocytochemical pattern of synovial fluid in rheumatoid arthritis, in related diseases and in posttraumatic effusions.
    Brühl W; Abgarowicz EM; Chwalińska-Sadowska H; Jakubowski S; Kalczak M; Maldyk H; Wagner T
    Reumatologia; 1970; 8(2):89-93. PubMed ID: 4915236
    [No Abstract]   [Full Text] [Related]  

  • 35. Sialic acid (N-acetylneuraminic acid) in the synovial fluid and serum of patients with inflammatory and non-inflammatory joint disease.
    Omdal R; Aurebekk B
    Scand J Rheumatol; 1985; 14(1):87-9. PubMed ID: 4001883
    [No Abstract]   [Full Text] [Related]  

  • 36. [Letter: Determination of fibrinogen degradation products in joint effusions].
    Cabanel G; Kolodie L; Gras JP; Pras P; Mouries D
    Nouv Presse Med; 1974 Apr; 3(14):895-6. PubMed ID: 4842512
    [No Abstract]   [Full Text] [Related]  

  • 37. Tenascin-C levels in synovial fluid are elevated after injury to the human and canine joint and correlate with markers of inflammation and matrix degradation.
    Chockalingam PS; Glasson SS; Lohmander LS
    Osteoarthritis Cartilage; 2013 Feb; 21(2):339-45. PubMed ID: 23142724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in chondroitin sulphate structure induced by joint disease.
    Hardingham T
    Acta Orthop Scand Suppl; 1995 Oct; 266():107-10. PubMed ID: 8553837
    [No Abstract]   [Full Text] [Related]  

  • 39. [Determination of the macromolecules in the extracellular matrix or of their antibodies in biological fluids in joint disease].
    Hartmann DJ; Ricard-Blum S; Ville G
    Rev Rhum Mal Osteoartic; 1989 Feb; 56(2):187-9. PubMed ID: 2727598
    [No Abstract]   [Full Text] [Related]  

  • 40. Reversal of aluminium dialysis encephalopathy after desferrioxamine treatment.
    Arze RS; Parkinson IS; Cartlidge NE; Britton P; Ward MK
    Lancet; 1981 Nov; 2(8255):1116. PubMed ID: 6118567
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.